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Background. Patients with chronic kidney disease (CKD) are
at high risk for cardiovascular disease, and despite recent ad-
vances in hypertension control, anemia management, and dial-
ysis adequacy, mortality remains high. Improved understanding
of nontraditional risk factors, including those present at early
phases in CKD, may lead to novel therapeutic strategies. CKD
has been demonstrated to be an independent risk factor for
cardiovascular disease in the general population, but data are
lacking as to the associated potential abnormalities that occur
in association with reduced glomerular filtration rate (GFR),
which may contribute to this increased risk. Data are accumulat-
ing regarding the role of abnormalities of calcium, phosphorus,
vitamin D, and parathyroid hormone (PTH) in cardiovascular
disease. Vitamin D deficiency is present even in the early stages
of CKD. Vitamin D plays a central role in calcium-phosphorus
homeostasis, regulation of PTH, and formation and mainte-
nance of bone. However, until recently, vitamin D has not been
considered to have a biologic role in CKD beyond mineral reg-
ulation, or has been considered as a negative factor contributing
to soft tissue and cardiovascular calcification. In light of recent
observational studies showing an association of vitamin D ther-
apy and survival benefit in hemodialysis patients, the effects
of vitamin D on cardiovascular system have become a heavily
debated issue.
Methods. A Medline search was performed to identify rele-
vant literature describing the role of vitamin D in the patho-
genesis of cardiovascular disease. Both the experimental and
clinical literatures in English were reviewed.
Results. The accumulating published data demonstrate both
associative relationships and mechanisms for biologic plausibil-
ity. The following three potential mechanisms may be important
for the protective effects of vitamin D against cardiovascular
disease mortality: vitamin D can inhibit various aspects of in-
flammation, which have been established as a key pathogenic
mechanism in atherosclerosis; vitamin D exerts an antiprolifer-
ative effect on myocardial cell hypertrophy and proliferation,
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which underlies the pathogenesis of congestive heart failure;
and vitamin D acts as a negative endocrine regulator for the
renin-angiotensin system, which itself plays an important inde-
pendent role in hypertension and cardiovascular health.
Conclusion. Vitamin D deficiency might be an underesti-
mated nonclassical risk factor for cardiovascular disease in
CKD. Based on a review of the evidence, from both basic science
and clinical studies, this article supports the possible protective
role of vitamin D beyond its effect on mineral metabolism, and
suggests the need for ongoing evaluation of the role of vitamin
D in cardiovascular health in the CKD population.
Vitamin D, in the form of 1,25-dihydroxyvitamin D3
and vitamin D analogues, is given primarily to treat sec-
ondary hyperparathyroidism and the associated calcium
and phosphate metabolic abnormalities of chronic kid-
ney disease (CKD). Recent observational studies [1, 2]
among patients on hemodialysis have indicated that vita-
min D treatment was associated with a significant reduc-
tion in the risk of all-cause death and of cardiovascular
death among these patients; while other studies have sug-
gested that excess vitamin D contributes to risk of hyper-
calcemia and vascular calcification, which is associated
with reduced survival and morbidity [3, 4]. Nonetheless,
there is accumulating evidence that vitamin D may in
fact be linked to cardiovascular processes in CKD pop-
ulations. Thus, this review examines the literature that
demonstrates the potential mechanisms of vitamin D in
cardiovascular protection that outside its effect on cal-
cium and phosphate metabolism.
CARDIOVASCULAR DISEASE IS ASSOCIATED
WITH CKD
Cardiovascular disease is more prevalent in patients
with CKD than in the general population [5], and is the
leading cause of death in patients with end-stage renal
disease (ESRD) [6]. Because of the high prevalence of
patients with CKD and their high risk for death, the
National Kidney Foundation Task Force on Cardiovas-
cular Disease has targeted two cardiovascular disease
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conditions, coronary artery disease and left ventricular
hypertrophy (LVH), when considering strategies that can
influence cardiovascular disease outcomes in CKD [6]. A
substantial amount of data exists to support the large bur-
den of cardiovascular disease in CKD populations. The
United States Renal Data System annual report cites that
34% of ESRD patients have concomitant coronary artery
disease or myocardial infarction. Other reports describe
the high prevalence of LVH prior to and at dialysis initi-
ation [7, 8]. Mortality due to cardiovascular disease has
been estimated to be 10 to 20 times higher in dialysis
patients than in the general population [9], and the Na-
tional Kidney Foundation Task Force on Cardiovascular
Disease recommends that CKD patients be considered
among the highest risk group for developing cardiovas-
cular disease [6].
CKD, AN INDEPENDENT RISK FACTOR
FOR CARDIOVASCULAR DISEASE
Patients with CKD often have many traditional car-
diovascular risk factors defined in the Framingham
Heart Study, such as older age, hypertension, diabetes,
hypertriglyceridemia, and low high-density lipoprotein
(HDL) cholesterol [10]. However, cross-sectional stud-
ies of CKD patients demonstrate that the Framingham
risk equation, which predicts cardiovascular disease risk
based on traditional risk factors, cannot explain all of the
cardiovascular disease risk in patients with CKD [9–11].
Recent studies have suggested that the presence of re-
duced glomerular filtration rate (GFR) itself is a risk fac-
tor for cardiovascular disease [12]. While some systematic
reviews have concluded that the findings from observa-
tional studies were equivocal [13], other long-term, ob-
servational studies in different age groups [14–17] have
provided evidence that reduced GFR is an independent
predictor of death and cardiovascular disease. The Joint
National Committee on Prevention, Detection, Evalua-
tion and Treatment of High Blood Pressure Seventh Re-
port has even stated that estimated GFR < 60 mL/min is
a major risk factor for cardiovascular disease [15, 18]. The
specific abnormalities associated with decreased GFR
that contribute to increased cardiovascular disease risk
remain to be defined.
ABNORMAL CALCIUM AND PHOSPHATE
METABOLISM IS ASSOCIATED WITH
WORSE OUTCOMES
Several nontraditional factors have been implicated as
risk factors for cardiovascular disease in CKD patients
[9], but are beyond the scope of this review. Increased
vascular and visceral calcifications, which are associated
with hyperphosphatemia and both hyperparathyroidism
and hypoparathyroidism, have been correlated with in-
creased risk of cardiovascular disease [19]. Atheroscle-
rotic plaques of ESRD patients have been found to
be more heavily calcified than nonuremic patients, with
thickening of the media layer but not of the intima [20,
21]. In comparison with nonuremic patients, ESRD pa-
tients have greater calcified transformation of plaques but
do not have greater extension of the plaque or a greater
number of early lesions [20]. London et al [22], evaluat-
ing the common carotid artery and blood vessels of the
pelvis and thigh in ESRD patients, found calcification
in both the media and the intima, and subsequently re-
lated this to abnormalities in serum phosphorus, calcium
and bone morphometry. Their work suggests that inti-
mal calcification occurs predominantly in older patients
with traditional cardiovascular risk factors, while medial
calcifications are found largely in younger patients with
longer duration of dialysis. In another study, Chertow et al
[23] used electron beam tomography to determine poten-
tial factors in the development of progressive coronary
and aortic artery calcification. The result showed that
calcium may directly or indirectly [through parathyroid
hormone (PTH)] influence the balance of skeletal and
extraskeletal calcification, but there was no association
between vitamin D use (or measured levels) and progres-
sive calcification. In their study, both types of calcification
were significantly associated with all-cause mortality and
cardiovascular mortality compared to patients with no
increased evidence of calcification [21]. Medial calcifica-
tions were more strongly associated with these endpoints,
although patients with intimal calcification had the worse
prognosis for all-cause mortality.
Observational clinical studies support hyperphos-
phatemia, abnormalities of parathyroid hormone and
increased vascular calcification as risk factors for car-
diovascular disease among CKD patients [24]. Longitu-
dinal data reveal an increased risk of death for ESRD
patients with serum phosphorus above 6.5 mg/dL and for
patients with calcium × phosphorus (Ca × P) product
above 72 mg2/dL2 [25]. An increased risk of death from
coronary artery disease has also been reported for pa-
tients with similarly elevated serum phosphorus levels,
and an increased risk of sudden death has been associ-
ated with elevated levels of serum phosphorus, Ca × P,
and PTH [25]. However, these data are based on adminis-
trative databases and are observational in nature, thus de-
scribing an association that requires further exploration.
A recent article by Stevens et al [26] further demon-
strates the increased probability of mortality associated
with different combinations of calcium, phosphorus, and
PTH, and suggests that different dialysis vintages and dif-
ferent constellations of these variables portend risk of
mortality, thus underscoring the complexity of the area.
Interestingly, serum calcium levels have been inconsis-
tently correlated with mortality risk; however, this may
be due to the lack of attention to vitamin D therapy as
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a possible confounder. A recent cohort study, presented
in preliminary form, analyzed the baseline distribution of
serum intact PTH (iPTH) and Ca × P levels by quintiles
in hemodialysis patients receiving paricalcitol, calcitriol,
or no vitamin D therapy in regard to their relationship
with hospitalization outcomes. The results showed no or
a weak association between serum iPTH and Ca × P with
morbidity among those treated with vitamin D analogues,
but a strong association among those not receiving vita-
min D treatment [27]. Thus, vitamin D therapy may be
a confounder for the association between morbidity and
PTH or Ca × P product: the benefit of vitamin D may be
unrelated to its effects on PTH or mineral control.
CLINICAL OUTCOMES WITH VITAMIN D
THERAPY, A POSSIBLE PROTECTIVE EFFECT
A number of recently published observational stud-
ies provide further support for a possible protective role
for vitamin D in the CKD population. These studies de-
scribed the effect of calcitriol and vitamin D analogues
on all-cause mortality and cardiovascular mortality
in patients on hemodialysis, and suggest an associa-
tion between vitamin D analogues and lower risk of
death and cardiovascular death. Using administrative
data, Teng et al [1] retrospectively analyzed the 3-year
survival rate of 67,399 patients on hemodialysis be-
tween 1999 and 2001. The analysis compared patients
treated with calcitriol to those treated with the vitamin
D analogue paricalcitol with the objective to determine
whether paricalcitol treatment, which results in less el-
evation in serum calcium and phosphorus levels than
calcitriol (previously studied by Sprague et al [28]), re-
sulted in a lower mortality rate. A Cox regression analy-
sis described an association of paricalcitol treatment with
both significantly less increase in serum calcium and phos-
phorus at 12 months, and a significantly higher survival
over the 36 months as compared to calcitriol. Caution
in interpretation of this nonrandomized, observational
data is important. However, the underlying protective
mechanism may extend beyond the impact on calcium
and phosphate metabolism, as the results showed that
the risk of death was significantly lower at all levels of
serum calcium, phosphorus, and PTH in the presence of
paricalcitol.
Importantly, Teng et al [1] did not include a nonvi-
tamin D–treated comparative group to evaluate the ef-
fects of calcitriol on outcome. Two other studies have
addressed this question. Tentori and associates have pre-
sented, in abstract form, an analysis of a large cohort of
approximately 8000 hemodialysis patients treated dur-
ing a similar time period and reported the comparative
survival rates of patients treated with calcitriol, parical-
citol, doxercalciferol (another vitamin D analogue), or
no treatment [29]. There were no major differences in
survival between those receiving any vitamin D supple-
ments; however, the hazard ratio (HR) for mortality was
significantly higher (1.2) in the no treatment group. No
significant differences in serum calcium levels among the
treatment groups were found, although the mean PTH
was higher in patients receiving paricalcitol and doxer-
calciferol than those treated with calcitriol. In another
observational study of 242 patients on chronic hemodial-
ysis, those treated with alfacalcidol, another vitamin D
analogue, were found to have a significantly lower risk of
death from cardiovascular causes than those with no vita-
min D treatment [2]. There were no significant differences
in noncardiovascular mortality. A step-wise multivariate
Cox analysis indicated that cardiovascular mortality was
significantly associated with age, presence of diabetes,
and inversely related to treatment with alfacalcidol.
Overall, the results of these observational studies
provide support for the hypothesis that there may be a
protective benefit of vitamin D therapy relative to no vita-
min D treatment in dialysis patients, which appears to be
separate from the direct impact of vitamin D on mineral
metabolism parameters.
HOW COULD VITAMIN D REDUCE
CARDIOVASCULAR MORTALITY? A CASE
FOR BIOLOGIC PLAUSIBILITY
The last decades have demonstrated that improv-
ing dialysis quality by increasing Kt/V and manage-
ment of anemia leads to an improved survival benefit in
hemodialysis patients, and that CKD patients may benefit
from control of hypertension, anemia, and other factors.
Nonetheless, survival still remains poor for the majority
of dialysis patients, and those with CKD remain more
likely to die of cardiovascular disease causes than to sur-
vive to dialysis. Interestingly, either relative or absolute
deficiency of vitamin D is present even in the early stages
of CKD [30]. Thus, it is possible, that vitamin D deficiency
may be one of the underrecognized, nonclassic risk fac-
tors for cardiovascular disease in CKD patients. Previous
work has viewed vitamin D primarily in terms of its role in
bone and calcium-phosphate metabolism; however, more
recent information has shown potentially unique actions
of vitamin D beyond these classic effects.
In particular, the vitamin D receptor, which mediates
the actions of vitamin D, has been found in almost every
organ, including the heart, the vascular wall, the kidney,
and immune cells [31–33]. As a ligand-activated transcrip-
tional factor, the vitamin D receptor regulates a large
number of genes involved not only in calcium and phos-
phate metabolism but also in other physiologic processes.
Therefore, it will be important to explore possible mech-
anisms which support the influence of vitamin D on car-
diovascular disease, independent of its effects on PTH
and calcium-phosphate homeostasis.
1976 Levin and Li: Vitamin D and cardiovascular disease
Table 1. Potential mechanisms involved in vitamin D protection of the cardiovascular system
Potential mechanisms Key evidence Key references Limitations
Anti-inflammation,
antiatherogenesis, and
protection against
blood vessel injury
Inhibition of antigen presenting cell
maturation, and functions; inhibition of
smooth muscle cell proliferation;
down-regulation of nuclear factor-j B
(NF-jB) activity, stimulation of
anti-inflammatory cytokine production; and
modulation of matrix metalloproteinase-9
(MMP-9) and C-reactive protein status
[38, 40–42] Experimental data of vitamin D
suppression of atherosclerosis
has yet to be established
Inhibition of cardiac
hypertrophy and
myocyte proliferation
Inverse relationship between vitamin D levels
and congestive heart failure; vitamin D
treatment reduces left ventricular
hypertrophy (LVH); vitamin D deficiency
or vitamin D receptor deficiency leads to
increase in blood pressure and myocardial
hypertrophyin rats and mice; and
suppression of endothelin-induced
cardiomyocyte hypertrophy and atrial
natriuretic peptide expression
[45, 46, 48, 49, 51, 58, 60] Direct experimental evidence for
vitamin D suppression of
cardiac hypertrophy in animal
models is still lacking
Regulation of the
renin-angiotensin
system
Inverse relationship between vitamin D levels
and plasma renin activity; vitamin D
treatment reduces blood pressure, cardiac
hypertrophy and plasma renin activity;
disruption of the vitamin D receptor gene
leads to elevated renin production, cardiac
hypertrophy, and high blood pressure in
mice; and transcriptional repression of
renin gene expression by vitamin D
[46, 54, 57–61] More studies are needed to
demonstrate the ability of
vitamin D or vitamin D
analogues to suppress plasma
renin activity and blood
pressure in hypertensive
animals and clinical trials
As shown in Table 1, three major potential mechanisms
may be important to explain the protective effects of vi-
tamin D against cardiovascular mortality: the regulation
of inflammation, the effect on myocardial cell hypertro-
phy and proliferation, and the regulation of the renin-
angiotensin system. Accumulating data from basic and
clinical studies do suggest a potential role for vitamin D
in cardiovascular health.
VITAMIN D AND INFLAMMATION
UNDERLYING ATHEROSCLEROSIS
Inflammation is now regarded as a key pathogenic
mechanism in atherosclerosis:the propagation of athero-
genic placques as a result of inflammatory processes is
well described, and beyond the scope of this review [34–
36]. Macrophages and T cells play a central role in the
inflammation process, the formation of foam cells and
atherosclerotic lesions on the arterial wall. The inflam-
matory response consists of release of cytokines, such
as interleukin (IL)-1, IL-4, IL-6, interferon (INF)-c and
tumor necrosis factor (TNF)-a, by macrophages and T
cells. These factors contribute to smooth muscle cell pro-
liferation and plaque formation, and increase the synthe-
sis and release of positive acute-phase proteins, such as
C-reactive protein (CRP) and amyloid A, and reduce
negative acute-phase proteins, such as albumin and trans-
ferrin. CRP has been demonstrated in numerous studies
to be predictive of cardiovascular disease and its long-
term outcomes [34]. Interestingly, high phosphate con-
centrations in the presence of high levels of PTH, which
are often associated with vitamin D deficiency, can also
induce smooth muscle cell proliferation and transforma-
tion to bone-forming cells [37].
VITAMIN D AND THE INFLAMMATORY
PROCESS
Vitamin D has long been known to possess immunoreg-
ulatory activities [38]. The immunomodulatory effects of
vitamin D are mediated by the vitamin D receptor, which
is present in most immune cells. Vitamin D appears to in-
hibit antigen-presenting cell maturation [39, 40], as well
as angiogenesis and vascular smooth muscle cell pro-
liferation [41]. Vitamin D also down-regulates nuclear
factor-jB (NF-jB) activity, increases IL-10 production
and decreases IL-6, IL-12, IFN-c, and TNF-a production,
leading to a cytokine profile which favors less inflamma-
tion [38].
Consistent with a possible protective role against
atherosclerosis, vitamin D has been shown to modu-
late the expression of tissue matrix metalloproteinases
(MMPs) [42]. MMPs are connective tissue enzymes se-
creted by activated macrophages during inflammatory
responses, and are involved in remodeling of the vas-
cular wall and myocardium. MMPs break down colla-
gen within the atherosclerotic lesion and cause lesion
rupture, leading to thrombosis [34–36]. Timms et al [42]
have analyzed the relationship between plasma levels
of CRP, MMP-9, tissue inhibitor of metalloproteinase
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Fig. 1. Inverse relationship between plasma
matrix metalloproteinase 9 (MMP-9) levels
and vitamin D status (25-hydroxyvitamin D).
These data were obtained from apparently
healthy subjects of Bangladeshi origin living
in London, United Kingdom (from Timms
et al, Q J Med 95:787–796, 2002, with
permission).
(TIMP-1) (a specific inhibitor of MMP), and serum levels
of vitamin D among an apparently healthy population
prone to vitamin D deficiency (Indo-Asian population),
and found that plasma MMP-9 levels inversely related
to vitamin D status (Fig. 1). Multiple linear regression
analysis indicated that vitamin D status was the only
independent determinant of CRP and MMP-9 levels.
When patients with vitamin D deficiency were treated
with three monthly cholecalciferol injections and evalu-
ated 1 year later, mean MMP-9, TIMP-1, and CRP levels
were decreased significantly from the pretreatment base-
line [42]. These results suggest that vitamin D may inhibit
various aspects of the inflammatory response to cardio-
vascular injury, and that in the presence of vitamin D
deficiency vitamin D administration may reduce
atherosclerotic plaque progression and plaque rupture.
Consistent with these findings, Watson et al [43] have re-
ported an inverse correlation between serum vitamin D
levels and coronary calcification, which also suggests a
protective role of vitamin D in atherogenesis.
Additional avenues of research that may further link
vitamin D to cardiovascular disease outcomes relate to
endothelial progenitor cells (EPCs). It is becoming evi-
dent that EPCs are associated with cardiovascular health
[44]. Interestingly, MMP-9 activation is one of the fac-
tors required for recruitment and mobilization of bone
marrow–derived EPCs, while CRP has been shown to
have a detrimental effect on EPC differentiation and
survival. Thus, vitamin D may be important in both the
prevention of inflammation and the stimulation of EPCs
from the bone marrow, thus affecting a number of key
biologic processes that have an impact on cardiovascular
health.
CARDIAC HYPERTROPHY AND EFFECTS
OF VITAMIN D
Vitamin D may also play a role indirectly in the patho-
genesis of congestive heart failure. Zitterman et al [45]
have evaluated 54 patients (20 patients <50 years old
and 34 patients ≥50 years old) with congestive heart fail-
ure (New York Heart Association classes ≥2) and com-
pared them with 34 normal subjects (≥50 years old). In
this study, levels of N-terminal proatrial natriuretic pep-
tide (NT-proANP), a predictor of congestive heart failure
and LVH severity, vitamin D metabolites, and parameters
of calcium metabolism were measured in fasting blood
samples. Both groups of congestive heart failure patients
had markedly increased serum levels of NT-proANP and
reduced circulating levels of 25-hydroxyvitamin D and
calcitriol, indicating an inverse relationship between vi-
tamin D levels and congestive heart failure. Moreover,
several small studies have demonstrated an impact of vi-
tamin D treatment on reduction of LVH among patients
on chronic hemodialysis. Although most of these studies
were of short duration and small sample size, Park et al
[46] demonstrated that 15 weeks of intravenous calcitriol
treatment of patients with ESRD and secondary hyper-
parathyroidism with LVH resulted in a marked reduction
in LVH (Fig. 2).
McGonigle et al [47] demonstrated that the base-
line serum 25-hydroxycholecalciferol was significantly
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Fig. 2. Changes of left ventricular mass (LVM) index before and af-
ter calcitriol therapy in hemodialysis patients with secondary hyper-
parathyroidism. The patients received intravenous injection of calcitriol
for 15 weeks (from Park et al, Am J Kidney Dis 33:73–81, 1999, with
permission).
and inversely correlated with left ventricular function,
and that after 6 weeks of intravenous treatment with
1a-hydroxycholecalciferol, there were small but signifi-
cant improvements in indices of left ventricular function.
Taken together, these small clinical studies support the
hypothesis that vitamin D may be protective for myocar-
dial structure and function.
The clinical findings have been corroborated by animal
and in vitro studies, which provide a potential mechanism
for explanation of these observations.
Weishaar and Simpson [48] and Weishaar et al [49] de-
scribed a series of experiments exploring the role of vi-
tamin D in myocyte proliferation and hypertrophy. They
demonstrated that vitamin D deficiency induced myocar-
dial hypertrophy, increased heart weight/body weight
ratio and extracellular matrix production in myocardial
tissue in rats. Moreover, 1,25-dihydroxyvitamin D3 treat-
ment inhibited cell proliferation of primary ventricular
myocytes isolated from neonatal rat hearts, which was
accompanied by down-regulation of c-myc and prolifer-
ating cell nuclear antigens (PCNAs) [50]. Using a similar
in vitro ventricular myocyte culture, Wu et al [51] found
that 1,25-dihydroxyvitamin D3 inhibited myocyte hyper-
trophy induced by endothelin and the expression of a-
skeletal actin and ANP gene, which were associated with
myocardial hypertrophy and heart failure. These findings
suggest that vitamin D plays an important role in car-
diac homeostasis and that its deficiency may increase the
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Fig. 3. Inverse relationship between plasma renin activity and 1,25-
dihydroxyvitmain D levels in patients with essential hypertension (from
Resnick et al, Ann Intern Med 105:649–654, 1986, with permission).
risk of cardiac hypertrophy through biologically plausible
mechanisms.
VITAMIN D REGULATION OF THE
RENIN-ANGIOTENSIN SYSTEM
Clinical and epidemiologic studies over the past
decades have demonstrated an inverse relationship be-
tween serum levels of 1,25-dihydroxyvitamin D3 and
blood pressure [52, 53] and/or plasma renin activity [54,
55] in normotensive and hypertensive subjects (Fig. 3).
It has been reported that 4-week treatment with vita-
min D and calcium reduced systolic blood pressure in
nonhypertensive elderly women who were vitamin D de-
ficient [56], and that 18-week vitamin D treatment re-
duced blood pressure in hypertensive subjects [57]. While
these are relatively short-term studies without cardio-
vascular events, they do describe important intermediate
outcomes in the development of cardiovascular disease.
In chronic hemodialysis patients with secondary hyper-
parathyroidism, the previously mentioned study by Park
et al [46] reported that 15 weeks of intravenous calcitriol
treatment regressed LVH, which was accompanied by a
significant reduction in plasma renin activity and plasma
angiotensin II levels. Taken together, accumulating clini-
cal data have provided evidence for a possible mechanism
whereby vitamin D suppresses plasma renin activity and
blood pressure. Therefore, either relative or absolute vi-
tamin D deficiency may be a contributing risk factor to
cardiovascular disease among CKD patients, and that vi-
tamin D may protect cardiovascular health through mod-
ulation of the renin-angiotensin system.
Li et al [58, 59] have recently explored the mech-
anism underlying the relationship between vitamin D
and the renin-angiotensin system using genetic animal
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Fig. 4. Stimulation of the renin-angiotensin
system in mutant mice lacking either the vi-
tamin D receptor (VDR) gene or the 25-
hydroxyvitamin D 1a-hydroxylase (1a-hyd)
gene. A marked increase in renin mRNA
transcript was seen in both vitamin D recep-
tor knockout mice (A) and 1a-hydroxylase
knockout mice (B). Left panels are North-
ern blot, and right panels are PhosphorImager
quantitative results of renin mRNA levels de-
tected by Northern blot analysis. ∗P < 0.01 vs.
wild-type mice.
models. Based on previous clinical and epidemiologic
findings, they hypothesized that vitamin D is a nega-
tive endocrine regulator of renin biosynthesis in vivo.
Consistent with this hypothesis, they found that renin
mRNA and protein levels in the kidney were markedly
increased in both vitamin D receptor knockout mice
and 25-hydroxyvitamin D 1a-hydroxylase knockout mice
(Fig. 4), indicating that intact vitamin D signaling is
required for maintaining a proper level of renin pro-
duction. They showed that plasma angiotensin II levels
were markedly elevated in vitamin D receptor knock-
out mice, while angiotensinogen expression in the liver
was not different from normal mice, indicating that the
plasma angiotensin II elevation was due to increased
renin activity. The vitamin D receptor knockout mice
developed hypertension and cardiac hypertrophy due
to the dysregulation of the renin-angiotensin system
[58, 60, 61]. Further studies demonstrated that normal
mice rendered vitamin D deficient also had increased
renin production, whereas 1,25-dihydroxyvitamin D3
treatment of normal mice resulted in renin suppression
[58]. These studies clearly support the observation that
1,25-dihydroxyvitamin D3 directly suppresses renin gene
expression, and this suppression is independent of the ef-
fect of vitamin D on calcium metabolism. Thus, vitamin
D appears to play a key role in renocardiovascular home-
ostasis by functioning as a negative endocrine regulator
of the renin-angiotensin system. These studies also pro-
vide a molecular basis to explore the potential of vitamin
D analogues as therapeutic renin inhibitors to control the
renin-angiotensin system and blood pressure [62].
FUTURE DIRECTIONS
Data from both experimental and clinical studies ap-
pear to support the concept that vitamin D deficiency
is associated with an increased risk for cardiovascular
disease in CKD populations. Although this role may
be, to some extent, mediated through elevated PTH
and calcium-phosphate metabolism, recent scientific ev-
idence suggests additional, possibly more relevant, bi-
ological mechanisms. Vitamin D may well modulate
and suppress the inflammatory response to blood ves-
sel injury, inhibit cardiomyocyte hypertrophy and pro-
liferation, and negatively regulate the renin-angiotensin
system. All of these effects may be equally or more
important than the effect of vitamin D on PTH and
calcium-phosphorus levels in the control of cardiovascu-
lar disease. However, there are limitations to these specu-
lated mechanisms, as some aspects of our analyses rely on
indirect evidence. Obviously, more direct experimental
data are needed to confirm these mechanisms (Table 1).
Given the biologic effects of vitamin D and the results
of observational studies that demonstrate an association
of vitamin D therapy and improved cardiovascular out-
comes in hemodialysis patients independent of calcium,
phosphate and PTH levels, further studies are now neces-
sary. Both observational and randomized controlled clin-
ical trials are necessary to confirm the beneficial effect
of vitamin D and analogues and to determine the impact
of vitamin D deficiency and supplementation on clinical
outcomes. Studies of biologic markers are also needed to
better understand the mechanisms and the relationship
of vitamin D therapy to clinical outcomes in all stages
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of CKD. In addition, it would be important to compare
the efficacy of different preparations of vitamin D ana-
logues to understand whether there are class effects or
differential effects of different preparations.
At the current time, it is not known at which level of
vitamin D deficiency to start treatment and whether the
effect is completely independent or partially related to
the presence of hyperparathyroidism. Given the substan-
tial number of patients with cardiovascular disease who
have compromised kidney function, the importance of vi-
tamin D in that population should be explored. Carefully
designed trials which are able to address these complex
questions will be able to determine the relative value of
vitamin D therapy on the modulation of cardiovascular
disease risk in CKD patients.
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